Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
Completed · Phase 2
Conditions studied: B-cell Lymphoma
In brief
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma. After the end of KTE-C19-112 (ZUMA-12), participants who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.
Key facts
- Study ID
- NCT03761056
- Run by
- Kite, A Gilead Company
- People needed
- 42
- Starts
- 2019-01-29
- Expected to finish
- 2023-10-12
- Last updated by the study team
- 2024-12-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Banner Health MD Anderson Cancer Center — Gilbert, Arizona, United States
- City of Hope — Duarte, California, United States
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
- Hopital Saint Louis — Paris, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.